Hammar Tora, Jonsén Emma, Björneld Olof, Askfors Ylva, Andersson Marine L, Lincke Alisa
The eHealth Institute, Department of Medicine and Optometry, Linnaeus University, S-391 82 Kalmar, Sweden.
Linnaeus University Centre for Data Intensive Sciences and Applications (LnuC DISA), Department of Computer Science and Media Technology (CM), Faculty of Technology, Linnaeus University, S-391 82 Kalmar, Sweden.
Pharmacy (Basel). 2024 Nov 15;12(6):168. doi: 10.3390/pharmacy12060168.
Adverse drug events (ADEs) occur frequently and are a common cause of suffering, hospitalizations, or death, and can be caused by harmful combinations of medications. One method used to prevent ADEs is by using (CDSSs). Janusmed Risk Profile is a CDSS evaluating the risk for nine common or serious ADEs resulting from combined pharmacodynamic effects. The aim of this study was to examine the prevalence of potential ADEs identified using CDSS algorithms from Janusmed Risk Profile. This retrospective, cross-sectional study covered the population of a Swedish region ( = 246,010 inhabitants in year 2020) using data on all medications dispensed and administered. More than 20% of patients had an increased risk of bleeding, constipation, orthostatism, or renal toxicity based on their medications. The proportion of patients with an increased risk varied from 3.5% to almost 30% across the nine categories of ADEs. A higher age was associated with an increased risk of potential ADEs and there were gender differences. A cluster analysis identified groups of patients with an increased risk for several categories of ADEs. This study shows that combinations of medications that could increase the risk of ADEs are common. Future studies should examine how this correlates with observed ADEs.
药物不良事件（ADEs）频繁发生，是痛苦、住院或死亡的常见原因，并且可能由药物的有害组合引起。用于预防ADEs的一种方法是使用临床决策支持系统（CDSSs）。Janusmed风险评估是一种CDSS，用于评估由联合药效学效应导致的九种常见或严重ADEs的风险。本研究的目的是调查使用Janusmed风险评估的CDSS算法识别出的潜在ADEs的患病率。这项回顾性横断面研究涵盖了瑞典一个地区的人口（2020年有246,010名居民），使用了所有配发和使用药物的数据。超过20%的患者基于其用药情况出现出血、便秘、体位性低血压或肾毒性风险增加。在九类ADEs中，风险增加的患者比例从3.5%到近30%不等。年龄越大，潜在ADEs的风险越高，并且存在性别差异。聚类分析确定了几类ADEs风险增加的患者群体。本研究表明，可能增加ADEs风险的药物组合很常见。未来的研究应考察这与观察到的ADEs如何相关。
